Low expression of circulating microRNA-328 is associated with poor prognosis in patients with acute myeloid leukemia
Related Experiment Video
Updated: Apr 6, 2026
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
Li Liu1, Ren'an Chen2, Yangping Zhang2
1Department of Haematology, Tangdu Hospital, Fourth Military Medical University, No.1, Xinsi Road, Xi'an, Shaanxi, 710038, People's Republic of China. lliu6699@126.com.
Background:
Dysregulation of circulating miR-328 has been identified in several tumors and is associated with prognosis of patients. However, the expression pattern of miR-328 and the impact on prognosis has not yet been studied in acute myeloid leukemia (AML). The purpose of this study is to investigate the expression status of miR-328 and its clinical significance in AML patients.
Methods:
RNA was extracted from plasma of 176 patients with newly diagnosed AML and 70 healthy volunteers. The miR-328 expression was examined by Realtime quantitative PCR. The association of circulating miR-328 expression with clinicopathological factors and prognosis of AML patients was statistically analyzed.
Results:
The expression of miR-328 was significantly downregulated in AML patients (median value 22.99, range: 3.63-242.0) compared with those of healthy controls (median value 89.17, range: 12.05-397.7; P < 0.001), and miR-328 expression was markedly increased in patients after treatment than before (23.40 ± 1.76 vs. 46.61 ± 3.83, P < 0.001). Moreover, low levels of miR-328 were associated with a higher white blood cell count and BM blast count (P = 0.026 and P = 0.003, respectively), and lower hemoglobin and platelet count (P = 0.004 and P = 0.022, respectively). Patients with low miR-328 expression had a relatively poor overall survival (P = 0.022) and shorter relapse-free survival (P = 0.008) than those with high miR-328 expression. In addition, low miR-328 expression was an independent prognostic factors for both OS (P = 0.017) and RFS (P = 0.023).
Conclusions:
Circulating miR-328 downregulation is a common event and is associated with poor clinical outcome in AML patients.
Insights
Circulating miR-328 is downregulated in acute myeloid leukemia (AML) patients and linked to poorer survival outcomes. This microRNA may serve as a prognostic biomarker for AML patients.
Area of Science:
- Oncology
- Molecular Biology
- Hematology
Background:
- Dysregulation of microRNA-328 (miR-328) is implicated in various cancers.
- The role of miR-328 in acute myeloid leukemia (AML) and its prognostic value remain uninvestigated.
Purpose of the Study:
- To investigate the expression levels of miR-328 in AML patients.
- To determine the clinical significance and prognostic impact of miR-328 in AML.
Main Methods:
- Plasma RNA was isolated from 176 newly diagnosed AML patients and 70 healthy controls.
- Real-time quantitative PCR was used to quantify miR-328 expression.
- Statistical analyses correlated miR-328 levels with clinicopathological factors and patient prognosis.
Main Results:
- miR-328 expression was significantly lower in AML patients compared to healthy controls (P < 0.001).
- Low miR-328 levels correlated with higher white blood cell and bone marrow blast counts, and lower hemoglobin and platelet counts.
- Reduced miR-328 expression was associated with poorer overall survival (OS) and relapse-free survival (RFS) (P = 0.022 and P = 0.008, respectively).
- Low miR-328 was identified as an independent prognostic factor for both OS and RFS (P = 0.017 and P = 0.023, respectively).
Conclusions:
- Downregulation of circulating miR-328 is a frequent occurrence in AML.
- Lower miR-328 expression is significantly associated with adverse clinical outcomes and serves as an independent prognostic marker in AML patients.
Related Concept Videos
01:22MicroRNAs
01:22MicroRNAs